COX-2 inhibitors – used clinically to reduce inflammation and pain – may find new applications for treating PTSD and other stress-related psychiatric disorders like major depression.

An inability to recognize faces may be an important mechanism underlying social inhibition and may contribute to, or maintain, social anxiety.

Harsh Trivedi, M.D., MBA, associate professor of Psychiatry, vice chair for Clinical Affairs for Vanderbilt’s Department of Psychiatry, and executive director and chief medical officer of Vanderbilt Behavioral Health, has been named CEO of Vanderbilt Psychiatric Hospital. He will remain administrative director for Vanderbilt Behavioral Health.

Vanderbilt researchers have established a link between the neurotransmitter serotonin and certain behaviors of some children with autism spectrum disorder (ASD), a link that may lead to new treatments for ASD.

Vanderbilt University scientists are a step closer to understanding how inflammation in the body can affect mood and behavior.

Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging (NIA) to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer’s disease.

Treating depressed individuals and figuring out who will and won’t respond to antidepressants is mostly trial and error — much to the frustration of patients and the health care providers who treat them.